公开(公告)号：SG10201608059VA

公开(公告)日：2016-11-29

申请号：SG10201608059V

申请日：2008-12-23

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： MATTHIESSEN PETER ,  TURECEK PETER ,  SCHWARZ HANS-PETER ,  SCHNECKER KURT

Abstract: The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.

公开(公告)号：CY1113869T1

公开(公告)日：2016-10-05

申请号：CY131100272

申请日：2013-04-02

Applicant: BAXTER INT

Inventor： SCHNECKER KURT ,  HAIDWEGER EVA ,  TURECEK PETER

IPC: A61K9/19 ,  A61K9/08 ,  A61K38/16 ,  A61K38/36 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K48/00

Abstract: Ηπαρούσαεφεύρεσηπαρέχειμακροπρόθεσμασταθεράφαρμακευτικάσκευάσματαλυοφιλιωμένουανασυνδυασμένουπαράγοντα von-Willebrand(rVWF) καιμεθόδουςπαρασκευήςκαιχορήγησηςαυτώντωνσκευασμάτων.

公开(公告)号：BRPI0920259A2

公开(公告)日：2016-01-05

申请号：BRPI0920259

申请日：2009-10-16

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： ROTTENSTEINER HANSPETER ,  SIEKMANN JUERGEN ,  TURECEK PETER

IPC: A61K47/48 ,  A61P7/02 ,  A61P7/04

公开(公告)号：AU2015242970A1

公开(公告)日：2015-11-05

申请号：AU2015242970

申请日：2015-10-13

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT ,  LIPOXEN TECHNOLOGIES LTD

Inventor： JAIN SANJAY ,  GREGORIADIS GREGORY ,  DWIVEDI ARCHANA ,  NATH SRIJIT ,  SIEKMANN JUERGEN ,  HAIDER STEFAN ,  ROTTENSTEINER HANSPETER ,  TURECEK PETER

IPC: A61K47/48

Abstract: A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.

公开(公告)号：NZ612320A

公开(公告)日：2015-06-26

申请号：NZ61232011

申请日：2011-12-16

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： ROTTENSTEINER HANSPETER ,  TURECEK PETER ,  SIEKMANN JUERGEN ,  SCHEINECKER RICHARD

IPC: A61K47/48 ,  A61P7/00

Abstract: Disclosed is a water soluble fatty acid derivative comprising a fatty acid or fatty acid ester attached to a water soluble linker, said fatty acid derivative stably attached to a therapeutic protein, wherein the water soluble linker comprises a water soluble polymer, at least one first functional group attached to the therapeutic protein, wherein the first functional group is an aminooxy group, and a second functional group attached to the fatty acid or fatty acid ester, wherein the second functional group is an aminooxy group.

公开(公告)号：PT2318050E

公开(公告)日：2014-12-02

申请号：PT09790935

申请日：2009-07-29

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： TURECEK PETER ,  SIEKMANN JUERGEN

IPC: A61K47/48 ,  C07K14/745

公开(公告)号：ES2521490T3

公开(公告)日：2014-11-12

申请号：ES07865679

申请日：2007-12-14

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： TURECEK PETER ,  SIEKMANN JUERGEN ,  SCHEIFLINGER FRIEDRICH ,  CANAVAGGIO MICHEL

IPC: A61K47/48 ,  A61P7/04

Abstract: Constructo proteináceo modificado químicamente que comprende a) una molécula de factor VII activado (FVIIa) seleccionado entre el grupo consistente en FVIIa plasmático y FVIIa recombinante (rFVIIa) y un derivado biológicamente activo de FVIIa que presenta una identidad de secuencia de aminoácidos superior al 90% con respecto al FVIIa de longitud completa; y b) al menos un ácido polisiálico que comprende de 1 a 4 unidades de ácido siálico unido a dicha molécula de FVIIa; donde el ácido polisiálico se enlaza de forma covalente directamente con al menos un residuo aminoácido de dicha molécula de FVIIa; y donde la vida media in vivo de dicho constructp en la sangre de un mamífero se prolonga en comparación con la vida media in vivo de una molécula de FVIIa que no está modificada químicamente.

公开(公告)号：AU2008345135B2

公开(公告)日：2014-02-13

申请号：AU2008345135

申请日：2008-12-23

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： MATTHIESSEN PETER ,  SCHWARZ HANS-PETER ,  TURECEK PETER ,  SCHNECKER KURT

IPC: B01D61/22 ,  A61K9/00 ,  A61K9/08 ,  A61K38/00

Abstract: The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.

公开(公告)号：ES2433601T3

公开(公告)日：2013-12-11

申请号：ES11009919

申请日：2009-10-20

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  NEKTAR THERAPEUTICS

Inventor： VARADI KATALIN ,  SCHRENK GERALD ,  ROTTENSTEINER HANSPETER ,  TURECEK PETER ,  WEBER ALFRED ,  ANDERLE HEINZ ,  CULBERTSON SEAN M ,  FANG ZHIHAO ,  ZAPPE HAROLD ,  ZHANG PING ,  BOSSARD MARY J

IPC: G01N33/542 ,  G01N33/58 ,  G01N33/68 ,  G01N33/86

Abstract: Un método in vitro de liberación de un polímero soluble en agua ligado de manera reversible de una proteínamodificada mediante el polímero soluble en agua o aumento de la actividad de una proteína modificada con unpolímero soluble en agua ligado de manera reversible que comprende la etapa de incubar la proteína en condicioneseficaces para liberar el polímero soluble en agua, en el que las condiciones eficaces para liberar el polímero solubleen agua comprenden aumentar la concentración de amina libre de un tampón que comprende la proteína por adiciónde lisina libre, histidina o una combinación de las mismas al tampón en una concentración eficaz para liberar elpolímero soluble en agua.

公开(公告)号：AU2013245489A1

公开(公告)日：2013-11-07

申请号：AU2013245489

申请日：2013-10-16

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： MATTHIESSEN PETER ,  ROMEDER-FINGER STEFAN ,  TURECEK PETER ,  SCHWARZ HANS-PETER

IPC: A61K38/48 ,  C07K1/18 ,  C12N9/64 ,  C12N15/57

Abstract: Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC TM resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC T M chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.